Johns Hopkins Identifies Claudin-4 as Receptor for 20%-Prevalence Gut Toxin Linked to Colon Cancer
Updated
Updated · ScienceDaily · Oct 31
Johns Hopkins Identifies Claudin-4 as Receptor for 20%-Prevalence Gut Toxin Linked to Colon Cancer
3 articles · Updated · ScienceDaily · Oct 31
Summary
Claudin-4 is the missing receptor that lets Bacteroides fragilis toxin bind colon cells, solving a mechanism that had eluded researchers for nearly 20 years.
CRISPR screening in colon epithelial cells showed that disabling the claudin-4 gene stopped toxin binding and prevented the toxin from reaching and cleaving E-cadherin.
Laboratory binding tests found a tight 1-to-1 toxin-receptor complex, suggesting BFT uses an unusual two-step attack rather than cutting its target directly.
Mouse experiments then used a soluble claudin-4 decoy to intercept the toxin and protect intestinal tissue from damage, pointing to a possible preventive strategy.
The work builds on a 2009 finding that the toxin promotes colon tumors, though researchers still need structural data and human studies to show cancer prevention.
Could a simple molecular decoy prevent a common gut bacterium from triggering colorectal cancer in healthy people?
Does the surrounding gut microbiome secretly help or hinder this toxic bacterium from hijacking our colon cells?
Without a precise 3D structure, how will scientists turn this newly discovered cancer-linked bacterial receptor into a viable drug?
Solving the BFT Mystery: Claudin-4 Docking Unlocks New Diagnostics and Decoy Therapies for Colorectal Cancer Risk
Overview
This report highlights the 2026 breakthrough discovery that claudin-4 is the essential receptor for Bacteroides fragilis toxin (BFT), solving a 15-year mystery in bacterial pathogenesis. Using a genome-wide CRISPR screen, researchers found that knocking out claudin-4 in colon cells protected them from BFT-induced damage, and double knockout with claudin-3 gave even stronger resistance. Biophysical studies confirmed BFT binds directly to claudin-4, enabling targeted decoy therapies that block toxin action in animal models. The report also explores how diet and diagnostics affect BFT risk, and discusses challenges in drug development, including the need to preserve gut barrier function while neutralizing the toxin.